Barts Health NHS Trust

London, City of London EC1A 7BE

0 studies enrolling now · 1 studies all time

What they study most

Metastatic gpNMB Over-expressing Triple Negative Breast Cancer

Studies at this site

• Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer — Completed